Executive Overview
The traditional architecture of pharmaceutical research and development (R&D) is undergoing a profound paradigm shift. For decades, the process of bringing a novel medicine from an initial concept to a patient’s bedside has been defined by astronomical financial costs, multi-year timelines, and an exceptionally high rate of scientific attrition. The vast majority of candidate molecules…